175 related articles for article (PubMed ID: 2053127)
1. Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin.
Brøsen K; Gram LF; Kragh-Sørensen P
Ther Drug Monit; 1991 Mar; 13(2):177-82. PubMed ID: 2053127
[TBL] [Abstract][Full Text] [Related]
2. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
Brøsen K; Klysner R; Gram LF; Otton SV; Bech P; Bertilsson L
Eur J Clin Pharmacol; 1986; 30(6):679-84. PubMed ID: 3533565
[TBL] [Abstract][Full Text] [Related]
3. The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study.
Skjelbo E; Gram LF; Brøsen K
Br J Clin Pharmacol; 1993 Mar; 35(3):331-4. PubMed ID: 8471415
[TBL] [Abstract][Full Text] [Related]
4. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine.
Brøsen K; Gram LF
Eur J Clin Pharmacol; 1989; 37(2):155-60. PubMed ID: 2792169
[TBL] [Abstract][Full Text] [Related]
5. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine.
Skjelbo E; Brøsen K; Hallas J; Gram LF
Clin Pharmacol Ther; 1991 Jan; 49(1):18-23. PubMed ID: 1988236
[TBL] [Abstract][Full Text] [Related]
6. First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype.
Brøsen K; Gram LF
Clin Pharmacol Ther; 1988 Apr; 43(4):400-6. PubMed ID: 3356084
[TBL] [Abstract][Full Text] [Related]
7. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine.
Brøsen K; Zeugin T; Meyer UA
Clin Pharmacol Ther; 1991 Jun; 49(6):609-17. PubMed ID: 2060250
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous high-performance liquid chromatography-electrochemical detection determination of imipramine, desipramine, their 2-hydroxylated metabolites, and imipramine N-oxide in human plasma and urine: preliminary application to oxidation pharmacogenetics.
Koyama E; Kikuchi Y; Echizen H; Chiba K; Ishizaki T
Ther Drug Monit; 1993 Jun; 15(3):224-35. PubMed ID: 8333003
[TBL] [Abstract][Full Text] [Related]
9. Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin.
Baumann P; Jonzier-Perey M; Koeb L; Küpfer A; Tinguely D; Schöpf J
Int Clin Psychopharmacol; 1986 Apr; 1(2):102-12. PubMed ID: 3571939
[TBL] [Abstract][Full Text] [Related]
10. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype.
Brøsen K; Otton SV; Gram LF
Clin Pharmacol Ther; 1986 Nov; 40(5):543-9. PubMed ID: 3769385
[TBL] [Abstract][Full Text] [Related]
11. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.
Madsen H; Nielsen KK; Brøsen K
Br J Clin Pharmacol; 1995 Apr; 39(4):433-9. PubMed ID: 7640151
[TBL] [Abstract][Full Text] [Related]
12. Polymorphic drug oxidation in humans.
Eichelbaum M
Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
[TBL] [Abstract][Full Text] [Related]
13. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine.
Brøsen K; Hansen JG; Nielsen KK; Sindrup SH; Gram LF
Eur J Clin Pharmacol; 1993; 44(4):349-55. PubMed ID: 8513845
[TBL] [Abstract][Full Text] [Related]
14. [Tricyclic antidepressants (imipramine, desipramine, amitriptyline, nortriptyline)].
Yasuda K
Nihon Rinsho; 1995 Feb; 53 Su Pt 1():934-7. PubMed ID: 8753592
[No Abstract] [Full Text] [Related]
15. d-Propoxyphene is a potent inhibitor of debrisoquine, but not S-mephenytoin 4-hydroxylation in vivo.
Sanz EJ; Bertilsson L
Ther Drug Monit; 1990 May; 12(3):297-9. PubMed ID: 2349617
[TBL] [Abstract][Full Text] [Related]
16. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations.
Alván G; Bechtel P; Iselius L; Gundert-Remy U
Eur J Clin Pharmacol; 1990; 39(6):533-7. PubMed ID: 2151318
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine.
Herchuelz A; Gangji D; Derenne F; Jeanniot JP; Douchamps J
Br J Clin Pharmacol; 1991 Jan; 31(1):73-6. PubMed ID: 2015173
[TBL] [Abstract][Full Text] [Related]
18. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.
Dayer P; Kronbach T; Eichelbaum M; Meyer UA
Biochem Pharmacol; 1987 Dec; 36(23):4145-52. PubMed ID: 3689440
[TBL] [Abstract][Full Text] [Related]
19. Imipramine metabolism in relation to the sparteine oxidation polymorphism--a family study.
Madsen H; Hansen TS; Brøsen K
Pharmacogenetics; 1996 Dec; 6(6):513-9. PubMed ID: 9014200
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of the sparteine/debrisoquine oxidation polymorphism.
Brøsen K; Gram LF
Eur J Clin Pharmacol; 1989; 36(6):537-47. PubMed ID: 2570698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]